Shield Therapeutics PLC logo

Shield Therapeutics PLC (1JS)

Market Closed
10 Jan, 20:00
XSTU XSTU
0. 02
-0
-4.08%
- Market Cap
- P/E Ratio
0% Div Yield
0 Volume
0 Eps
0.02
Previous Close
Day Range
0.02 0.02
Year Range
0.01 0.08

Summary

1JS closed Friday lower at €0.02, a decrease of 4.08% from Thursday's close, completing a monthly decrease of -6% or €0. Over the past 12 months, 1JS stock lost -6%.
1JS is not paying dividends to its shareholders.
The last earnings report, released on Sep 26, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XSTU (EUR).
Want to track 1JS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

1JS Chart

FAQ

What Is the Shield Therapeutics PLC(1JS) Stock Price Today?

The 1JS stock price today is €0.02.

What Stock Exchange Does Shield Therapeutics PLC Trade On?

Shield Therapeutics PLC is listed and trades on the XFRA.

What Is the Stock Symbol for Shield Therapeutics PLC?

The stock symbol for Shield Therapeutics PLC is "1JS".

Does Shield Therapeutics PLC Pay Dividends? What's The Current Dividend Yield?

1JS is not paying dividends to its shareholders.

What Is the Shield Therapeutics PLC Market Cap?

As of today, Shield Therapeutics PLC does not have a market cap available.

Did Shield Therapeutics PLC had any splits?

No, Shield Therapeutics PLC has never had a stock split.

Shield Therapeutics PLC Profile

Drug Manufacturers - Specialty & Generic Industry
Healthcare Sector
Mr. Anders Lundstrom CEO
XSTU Exchange
GB00BYV81293 ISIN
United Kingdom Country
73 Employees
- Last Dividend
- Last Split
- IPO Date
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.

Contact Information

Address: Northern Design Centre
Phone: 44 1915 118 500